IMPROVEMENTS WITH RESLIZUMAB TREATMENT IN PATIENT-REPORTED SLEEP QUALITY IN PATIENTS WITH INADEQUATELY CONTROLLED EOSINOPHILIC ASTHMA

Abstract

Introduction Nighttime awakenings are a cardinal sign of poorly controlled asthma. Reslizumab is an anti-interleukin-5 monoclonal antibody that reduces asthma exacerbations and improves lung function, asthma control, and quality of life in patients with inadequately controlled eosinophilic asthma (Castro et al., Lancet Resp Med. 2015). The aim of this analysis was to assess whether treatment with reslizumab can improve patient-reported sleep outcomes in patients with asthma. Methods Patients with inadequately controlled moderate-to-severe asthma participated in two 52-week placebo-controlled Phase 3 studies of IV reslizumab (3mg/kg Q4W). Patients were 12–75 years of age, with ≥1 CAE in the previous year and blood eosinophils ≥400/µL. In a post-hoc analysis of data from patients who completed the Asthma Quality of Life Questionnaire (AQLQ), the effect of IV reslizumab on the sleep-related AQLQ questions (Q5 [sleep limitation]; Q24 [awakenings]; Q29 [sleep interference]) was assessed. Results Patients receiving reslizumab (n=477) had significantly greater improvement over 52 weeks in each of the sleep-related AQLQ question scores versus placebo (n=476) (mean [95% CI] treatment effects for Q5, Q24 and Q29 were 0.295 [0.167, 0.422], 0.364 [0.223, 0.504] and 0.343 [0.195, 0.492], respectively; all p Conclusions Patients with inadequately controlled asthma treated with IV reslizumab had significantly greater improvement over 52 weeks versus placebo in sleep quality, as measured by the three sleep-related AQLQ questions.